

The Board of Directors resolves to prepare a balance sheet for liquidation purposes

Gothenburg, Sweden - The Board of Directors of LIDDS AB (publ) has resolved to prepare a control balance sheet for liquidation purposes. The decision has been made due to reasons to believe that the Company's equity is less than one-half of the registered share capital.

Due to the Company's decision to write-down intangible assets and continued negative results, the Board of Directors of LIDDS AB (publ) has found reasons to believe that the equity is less than one-half of the registered share capital. Therefore, the Board has decided to prepare and have the Company's auditor review a balance sheet for liquidation purposes in accordance with the Swedish Companies Act, with the aim of investigating whether the Company's equity is less than one-half of the registered share capital.

The Company will now, together with its auditor, work to finalize the balance sheet for liquidation purposes. As soon as the balance sheet has been prepared and reviewed by the Company's auditor, the outcome will be announced. If the balance sheet shows that the equity is less than one-half of the registered share capital, the Board will convene a first control meeting in accordance with the Swedish Companies Act.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

Daniel Lifveredson, Chairman of the Board
Telefon: +46 (0) 70-916 21 01
Email: d.li@excore.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-22 08:10 CEST.

Attachments

The Board of Directors resolves to prepare a balance sheet for liquidation purposes